Results 191 to 200 of about 2,582,733 (281)

Erratum: Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355-372]. [PDF]

Acta Pharm Sin B, 2022
Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Ouyang L.   +7 more
europepmc   +1 more source

Tyrosine kinase as therapeutic target of neurodegenerative disorders

Brain Disorders
Classes of hereditary and sporadic illnesses known as neurodegenerative diseases are linked to gradual nervous system malfunction and neuronal death. Protein kinases are an increasingly popular class of pharmacological targets for disorders affecting ...
Dipanjan Karati, Dileep Kumar
doaj  

Peer Review #2 of "A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma (v0.2)"

, 2019

openalex   +2 more sources

Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors. [PDF]

JCO Precis Oncol, 2021
Bokemeyer C, Vassal G, Italiano A, De La Cuesta E, Hiemeyer F, Fellous M, Marian M.   +6 more
europepmc   +1 more source

B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer [PDF]

Journal of Thoracic Oncology, 2020
Anna F. Farago, A. Drilon, Ulrik Lassen, Shivaani Kummar, David M. Hyman, Victor Moreno, Lee S. Rosen, Jyoti D. Patel, Barrett H. Childs   +8 more
openaire   +2 more sources

HYDROGEN SULFIDE IMPROVES ABERRANT GASTRIC SMOOTH MUSCLE FUNCTION IN DUCHENNE MUSCULAR DYSROPHY MICE [PDF]

, 2019
Deficiency of dystrophin, a cytoskeletal protein localized in the inner face of the plasma membrane in skeletal, cardiac and smooth muscle, results in Duchenne Muscular Dystrophy (DMD).
Randhawa, Gurpreet
core   +1 more source

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. [PDF]

JCO Precis Oncol, 2022
Treis D, Umapathy G, Fransson S, Guan J, Mendoza-García P, Siaw JT, Wessman S, Gordon Murkes L, Stenman JJE, Djos A, Elfman LHM, Johnsen JI, Hallberg B, Palmer RH, Martinsson T, Kogner P.   +15 more
europepmc   +1 more source

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Acta Pharmaceutica Sinica B
Neurotrophic receptor kinase (NTRK) fusions are actionable oncogenic drivers of multiple pediatric and adult solid tumors, and tropomyosin receptor kinase (TRK) has been considered as an attractive therapeutic target for “pan-cancer” harboring these ...
Shuang Xiang, Xiaoyun Lu
doaj  

Dysregulated tropomyosin receptor kinase (Trk) signalling in CYLD mutant tumours

, 2010
Neil Rajan, Richard Elliott, C.J. Lord, Oliver Clewes, John Burn, Maya Sieber‐Blum, Alan Ashworth   +6 more
openalex   +1 more source

Dual Inhibition of IL-2-Inducible T-Cell Kinase (ITK) and Tropomyosin Receptor Kinase A (TRKA) as Potential Treatment for Atopic Dermatitis and Other Inflammatory and Autoimmune Diseases. [PDF]

ACS Med Chem Lett, 2021
Abdel-Magid AF.
europepmc   +1 more source